Atherogenic Dyslipidaemia and Residual CV Risk – MM1705
Statin therapy has long been the cornerstone of cardiovascular disease (CVD) prevention for reducing levels of atherogenic low-density lipoprotein cholesterol (LDL-c). Therapy solely directed at reducing LDL-c levels will not address other lipid abnormalities present [eg, high levels of triglycerides (TGs) and/or low levels of high-density lipoprotein cholesterol (HDL-c)], which contribute to the presence of a residual risk of CV events.
Modern Medicine – May 2017
